HCV Tappt Adherence Study

Launched by UNIVERSITY OF ILLINOIS AT CHICAGO · Feb 8, 2024

Keywords

ClinConnect Summary

The HCV Tappt Adherence Study is looking into a new digital tool called Tappt, designed to help people with hepatitis C (HCV) stick to their daily medication routines. The main goal of this study is to see if using the Tappt app can help patients take their medications as prescribed, finish their treatment, and achieve a positive outcome, which means the virus is no longer detectable in their blood. Participants will download the app to track their medication use, and pharmacists will use this information to tailor support based on any challenges that patients report.

To join this study, you need to be at least 18 years old and diagnosed with hepatitis C. You should be starting medication specifically for HCV and have access to a smartphone for using the app. If you're interested, you’ll need to be able to understand and agree to the study in English. It's important to note that pregnant individuals and those with certain severe liver conditions cannot participate. Throughout the study, you'll receive support from healthcare professionals to help you stay on track with your treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. 18 years of age or older
• • 2. Hepatitis C virus (HCV) infection (denoted by positive HCV antibody and detectable HCV RNA)
• • 3. Initiating oral HCV therapy with glecaprevir/pibrentasvir or sofosbuvir/velpatasvir
• • 4. HCV treatment provided and managed by the clinical pharmacist at UI Health
• • 5. Access to a mobile smartphone (iPhone 7 or later; Android release date 2012 or later) with reliable data and/or Wi-Fi access
• • 6. Ability to verbalize understanding of the study protocol in English
• • 7. Able and willing to provide informed consent in English
• Exclusion Criteria:
• • 1. Inability to speak and read English
• • 2. Inability or unwillingness to adhere to the study protocol
• • 3. Pregnant individuals
• • 4. Decompensated cirrhosis (Child Turcotte Pugh Class B and C); hepatocellular carcinoma; prior liver or kidney transplant
• • No patient will be excluded because of gender, race or ethnic origin.
• The following populations will be excluded from the study:
• • Adults 18 years of age and older who are unable or unwilling to consent
• • Individuals less than 18 years old
• • Pregnant individuals
• • Prisoners